vs
Side-by-side financial comparison of Loar Holdings Inc. (LOAR) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $131.8M, roughly 1.2× Loar Holdings Inc.). Loar Holdings Inc. runs the higher net margin — 9.5% vs -82.0%, a 91.5% gap on every dollar of revenue. On growth, Loar Holdings Inc. posted the faster year-over-year revenue change (19.3% vs -22.7%). Over the past eight quarters, Loar Holdings Inc.'s revenue compounded faster (19.8% CAGR vs -11.5%).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
LOAR vs PTCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $131.8M | $164.7M |
| Net Profit | $12.5M | $-135.0M |
| Gross Margin | 52.1% | — |
| Operating Margin | 18.0% | -43.3% |
| Net Margin | 9.5% | -82.0% |
| Revenue YoY | 19.3% | -22.7% |
| Net Profit YoY | 239.5% | -104.8% |
| EPS (diluted) | $0.13 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $131.8M | $164.7M | ||
| Q3 25 | $126.8M | $211.0M | ||
| Q2 25 | $123.1M | $178.9M | ||
| Q1 25 | $114.7M | $1.2B | ||
| Q4 24 | $110.4M | $213.2M | ||
| Q3 24 | $103.5M | $196.8M | ||
| Q2 24 | $97.0M | $186.7M | ||
| Q1 24 | $91.8M | $210.1M |
| Q4 25 | $12.5M | $-135.0M | ||
| Q3 25 | $27.6M | $15.9M | ||
| Q2 25 | $16.7M | $-64.8M | ||
| Q1 25 | $15.3M | $866.6M | ||
| Q4 24 | $3.7M | $-65.9M | ||
| Q3 24 | $8.7M | $-106.7M | ||
| Q2 24 | $7.6M | $-99.2M | ||
| Q1 24 | $2.2M | $-91.6M |
| Q4 25 | 52.1% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 52.1% | — | ||
| Q4 24 | 48.9% | — | ||
| Q3 24 | 51.1% | — | ||
| Q2 24 | 49.0% | — | ||
| Q1 24 | 48.4% | — |
| Q4 25 | 18.0% | -43.3% | ||
| Q3 25 | 22.9% | 1.4% | ||
| Q2 25 | 22.2% | -19.5% | ||
| Q1 25 | 22.8% | 82.5% | ||
| Q4 24 | 19.2% | -76.2% | ||
| Q3 24 | 22.1% | -27.7% | ||
| Q2 24 | 22.9% | -21.5% | ||
| Q1 24 | 23.3% | -21.6% |
| Q4 25 | 9.5% | -82.0% | ||
| Q3 25 | 21.8% | 7.5% | ||
| Q2 25 | 13.6% | -36.3% | ||
| Q1 25 | 13.4% | 73.7% | ||
| Q4 24 | 3.3% | -30.9% | ||
| Q3 24 | 8.4% | -54.2% | ||
| Q2 24 | 7.9% | -53.1% | ||
| Q1 24 | 2.4% | -43.6% |
| Q4 25 | $0.13 | $-1.63 | ||
| Q3 25 | $0.29 | $0.20 | ||
| Q2 25 | $0.17 | $-0.83 | ||
| Q1 25 | $0.16 | $10.04 | ||
| Q4 24 | $-11023.48 | $-0.85 | ||
| Q3 24 | $0.09 | $-1.39 | ||
| Q2 24 | $0.09 | $-1.29 | ||
| Q1 24 | $11023.54 | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.8M | $1.9B |
| Total DebtLower is stronger | $715.7M | — |
| Stockholders' EquityBook value | $1.2B | $-205.3M |
| Total Assets | $2.0B | $2.9B |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.8M | $1.9B | ||
| Q3 25 | $99.0M | $1.7B | ||
| Q2 25 | $103.3M | $2.0B | ||
| Q1 25 | $80.5M | $2.0B | ||
| Q4 24 | $54.1M | $1.1B | ||
| Q3 24 | $55.2M | $1.0B | ||
| Q2 24 | $73.2M | $1.1B | ||
| Q1 24 | $28.2M | $884.8M |
| Q4 25 | $715.7M | — | ||
| Q3 25 | $279.4M | — | ||
| Q2 25 | $277.7M | — | ||
| Q1 25 | $277.5M | — | ||
| Q4 24 | $277.3M | — | ||
| Q3 24 | $602.1M | — | ||
| Q2 24 | $250.7M | — | ||
| Q1 24 | $534.2M | — |
| Q4 25 | $1.2B | $-205.3M | ||
| Q3 25 | $1.2B | $-155.8M | ||
| Q2 25 | $1.1B | $-206.5M | ||
| Q1 25 | $1.1B | $-185.8M | ||
| Q4 24 | $1.1B | $-1.1B | ||
| Q3 24 | $769.8M | $-1.1B | ||
| Q2 24 | $758.4M | $-980.2M | ||
| Q1 24 | $420.6M | $-893.9M |
| Q4 25 | $2.0B | $2.9B | ||
| Q3 25 | $1.5B | $2.6B | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.5B | $2.7B | ||
| Q4 24 | $1.5B | $1.7B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.1B | $1.9B | ||
| Q1 24 | $1.1B | $1.8B |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 1.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-36.6M |
| FCF MarginFCF / Revenue | — | -22.3% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 2.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-34.3M | ||
| Q3 25 | $29.7M | $-66.3M | ||
| Q2 25 | $23.8M | $-58.3M | ||
| Q1 25 | $28.4M | $870.1M | ||
| Q4 24 | $20.7M | $-30.0M | ||
| Q3 24 | $16.3M | $-77.0M | ||
| Q2 24 | $7.1M | $-71.5M | ||
| Q1 24 | $10.8M | $70.8M |
| Q4 25 | — | $-36.6M | ||
| Q3 25 | — | $-69.7M | ||
| Q2 25 | — | $-59.6M | ||
| Q1 25 | — | $868.4M | ||
| Q4 24 | — | $-33.8M | ||
| Q3 24 | — | $-77.5M | ||
| Q2 24 | — | $-78.8M | ||
| Q1 24 | — | $61.2M |
| Q4 25 | — | -22.3% | ||
| Q3 25 | — | -33.1% | ||
| Q2 25 | — | -33.3% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | -15.8% | ||
| Q3 24 | — | -39.4% | ||
| Q2 24 | — | -42.2% | ||
| Q1 24 | — | 29.1% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 4.0% | ||
| Q1 24 | — | 4.6% |
| Q4 25 | 2.43× | — | ||
| Q3 25 | 1.08× | -4.17× | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.85× | 1.00× | ||
| Q4 24 | 5.62× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 4.81× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
PTCT
Segment breakdown not available.
